{"id":"NCT04542694","sponsor":"Promomed, LLC","briefTitle":"Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","officialTitle":"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-21","primaryCompletion":"2020-08-10","completion":"2020-08-20","firstPosted":"2020-09-09","resultsPosted":"2020-11-05","lastUpdate":"2020-11-05"},"enrollment":200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Favipiravir","otherNames":["AREPLIVIR"]},{"type":"DRUG","name":"Standard of care","otherNames":[]}],"arms":[{"label":"Favipiravir (Areplivir)","type":"EXPERIMENTAL"},{"label":"Standard of care","type":"ACTIVE_COMPARATOR"}],"summary":"This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.","primaryOutcome":{"measure":"Rate of Clinical Status Improvement","timeFrame":"By Visit 3, approximately 10 days","effectByArm":[{"arm":"Favipiravir (Areplivir)","deltaMin":27,"sd":null},{"arm":"Standard of Care","deltaMin":15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0372"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":100},"commonTop":["Increased alanine aminotransferase activity","Increased aspartate aminotransferase activity"]}}